TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

Trends in Immunology

Volumn 38, Issue 1, 2017, Pages 20-28

  Manieri, Nicholas A ^a   Chiang, Eugene Y ^a   Grogan, Jane L ^a  

^a Department of Cancer Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TIGIT PROTEIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TIGIT PROTEIN, HUMAN;

CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 85002765709     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.10.002     Document Type: Review

References (45)

1. 1 Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
2. 2 Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15 (2015), 486–499.
3. 3 Postow, M.A., et al. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33 (2015), 1974–1982.
4. 4 Wolchok, J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
5. 5 Postow, M.A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372 (2015), 2006–2017.
6. 6 Larkin, J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
7. 7 Le Mercier, I., et al. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front. Immunol., 6, 2015, 418.
8. 8 Yu, X., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10 (2009), 48–57.
9. 9 Levin, S.D., et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur. J. Immunol. 41 (2011), 902–915.
10. 10 Boles, K.S., et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur. J. Immunol. 39 (2009), 695–703.
11. 11 Lozano, E., et al. The TIGIT/CD226 axis regulates human T cell function. J. Immunol. 188 (2012), 3869–3875.
12. 12 Joller, N., et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40 (2014), 569–581.
13. + T cell effector function. Cancer Cell 26 (2014), 923–937.
14. 14 Stengel, K.F., et al. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis–trans receptor clustering. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 5399–5404.
15. 15 Zhu, Y., et al. Identification of CD112R as a novel checkpoint for human T cells. J. Exp. Med. 213 (2016), 167–176.
16. 16 Liu, J., et al. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. J. Immunol. 188 (2012), 5511–5520.
17. 17 Tahara-Hanaoka, S., et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 107 (2006), 1491–1496.
18. 18 Fabre, S., et al. Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C’-C’-D beta-strands of the nectin1 V domain. J. Biol. Chem. 277 (2002), 27006–27013.
19. 19 Sakisaka, T., Takai, Y., Biology and pathology of nectins and nectin-like molecules. Curr. Opin. Cell Biol. 16 (2004), 513–521.
20. 20 Joller, N., et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. 186 (2011), 1338–1342.
21. 21 Stanietsky, N., et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 17858–17863.
22. 22 Stanietsky, N., et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur. J. Immunol. 43 (2013), 2138–2150.
23. 23 Liu, S., et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 20 (2013), 456–464.
24. 24 Li, M., et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J. Biol. Chem. 289 (2014), 17647–17657.
25. 25 Gur, C., et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42 (2015), 344–355.
26. 26 Wang, F., et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur. J. Immunol. 45 (2015), 2886–2897.
27. 27 Sarhan, D., et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res. 76 (2016), 5696–5706.
28. 28 Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182 (2009), 4499–4506.
29. 29 Rhee, I., Diverse macrophages polarization in tumor microenvironment. Arch. Pharm. Res., 2016 Published online August 25, 2016 http://dx.doi.org/10.1007/s12272-016-0820-y.
30. 30 Chen, X., et al. TIGIT negatively regulates inflammation by altering macrophage phenotype. Immunobiology 221 (2016), 48–55.
31. 31 Burton, B.R., et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat. Commun., 5, 2014, 4741.
32. 32 Kourepini, E., et al. TIGIT enhances antigen-specific Th2 recall responses and allergic disease. J. Immunol. 196 (2016), 3570–3580.
33. 33 Fuhrman, C.A., et al. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J. Immunol. 195 (2015), 145–155.
34. 34 Kurtulus, S., et al. TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Invest. 125 (2015), 4053–4062.
35. + T cells in melanoma patients. J. Clin. Invest. 125 (2015), 2046–2058.
36. + T-cell exhaustion and poor clinical outcome in AML patients. Clin. Cancer Res. 22 (2016), 3057–3066.
37. 37 Inozume, T., et al. Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J. Invest. Dermatol. 136 (2016), 255–263.
38. 38 Chan, C.J., et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15 (2014), 431–438.
39. 39 Fuchs, A., Colonna, M., The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin. Cancer Biol. 16 (2006), 359–366.
40. 40 Fuchs, A., et al. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J. Immunol. 172 (2004), 3994–3998.
41. 41 Blackburn, S.D., et al. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 15016–15021.
42. + T cells cooperate to contain chronic viral infection. Science 338 (2012), 1220–1225.
43. + T cells curtail chronic viral infection. Nature 537 (2016), 412–428.
44. + T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
45. hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J. Clin. Invest. 119 (2009), 2648–2662.